Omega Diagnostics Group PLC (GB:CNSL)
LSE:CNSL
Want to see GB:CNSL full AI Analyst Report?
CNSL Stock Chart & Stats
2.30 p
-0.05 p(-1.67%)
At close: 4:00 PM EST
2.30 p
-0.05 p(-1.67%)
Day’s Range― - ―
52-Week Range1.70 p - 4.33 p
Previous CloseN/A
Volume6.91K
Average Volume (3M)353.57K
Market Cap
£4.76M
Enterprise Value1.40M
Total Cash (Recent Filing)£3.59M
Total Debt (Recent Filing)£237.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Jul 29, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding237,950,650
10 Day Avg. Volume111,535
30 Day Avg. Volume353,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.87
P/FCF Ratio-51.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt-to-equity ratio (0.03) and a ROE of 13.73% provide material financial flexibility. Low leverage reduces refinancing and insolvency risk, enabling the company to support contract manufacturing commitments, absorb shocks, or invest in product development without heavy external borrowing.
Strong Gross MarginsA gross margin around 60% implies strong product economics and pricing power in diagnostics reagents and kits. High gross margins create a durable buffer for operating expenses, support reinvestment in R&D and capacity, and improve the potential profitability of scaling or CMO engagements.
Recurring Consumables & CMOA business mix of repeat consumables and contract development/manufacturing generates recurring revenue streams and long-term customer relationships. This model stabilizes demand, raises lifetime customer value, and improves capacity utilization versus one-off product sales, supporting steady cash inflows if execution holds.
Bears Say
Declining RevenueSustained negative revenue growth erodes economies of scale and can reflect weakening demand or competitive pressure. Declining top-line limits the company’s ability to cover fixed costs, reduces funds available for R&D or commercialization, and risks turning profitable gross margins into persistent operating losses.
Weak Cash GenerationSeverely deteriorating free cash flow and very low cash conversion from earnings indicate structural cash-generation problems. Persistent negative FCF raises liquidity risk, may force external financing, constrain capex and inventory for diagnostics production, and limits strategic flexibility over months to years.
Operating InefficiencyA negative EBIT margin despite healthy gross margins points to high operating costs or inefficiencies. If structural, these pressures undermine sustainable profitability, require meaningful cost restructuring or pricing shifts, and increase the risk that revenue volatility translates into sustained earnings weakness.
Omega Diagnostics News
CNSL FAQ
What was Omega Diagnostics Group PLC’s price range in the past 12 months?
Omega Diagnostics Group PLC lowest share price was 1.70 p and its highest was 4.33 p in the past 12 months.
What is Omega Diagnostics Group PLC’s market cap?
Omega Diagnostics Group PLC’s market cap is £4.76M.
When is Omega Diagnostics Group PLC’s upcoming earnings report date?
Omega Diagnostics Group PLC’s upcoming earnings report date is Jul 29, 2026 which is in 90 days.
How were Omega Diagnostics Group PLC’s earnings last quarter?
Omega Diagnostics Group PLC released its earnings results on Nov 10, 2025. The company reported 0 p earnings per share for the quarter, the consensus estimate of N/A by 0 p.
Is Omega Diagnostics Group PLC overvalued?
According to Wall Street analysts Omega Diagnostics Group PLC’s price is currently Overvalued.
Does Omega Diagnostics Group PLC pay dividends?
Omega Diagnostics Group PLC does not currently pay dividends.
What is Omega Diagnostics Group PLC’s EPS estimate?
Omega Diagnostics Group PLC’s EPS estimate is >-0.01.
How many shares outstanding does Omega Diagnostics Group PLC have?
Omega Diagnostics Group PLC has 237,950,650 shares outstanding.
What happened to Omega Diagnostics Group PLC’s price movement after its last earnings report?
Omega Diagnostics Group PLC reported an EPS of 0 p in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -15.094%.
Which hedge fund is a major shareholder of Omega Diagnostics Group PLC?
Currently, no hedge funds are holding shares in GB:CNSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Omega Diagnostics Group PLC
Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.
Technical Analysis
Advanced Medical Solutions
―
EKF Diagnostics Holdings
―
IXICO plc
―
Tristel
―
Abingdon Health PLC
―
Options Prices
Currently, No data available
---